Regarding clinical actionability, the EXT1 variant has implications for differential diagnosis [45], the BRCA1 variant for therapy selection, and both the BRCA1 and the BRIP1 variants are clinically relevant for risk assessment, prevention, prophylaxis and early detection of their associated cancers [49] (Supplementary Table 4). The gene discussed is BRCA1; the disease is cancer.